Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.
Gain Therapeutics SA Announces Award of Grant Support from Leading
Is Gain Therapeutics Inc (GANX) a Good Buy in the Biotechnology
Buy Gain Therapeutics Stock - GANX Stock Price Today & News
Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock
Home Perspectives from Gain Therapeutics
GANX Insider Trading Activity - Gain Therapeutics Inc.
Gain Therapeutics Presents New Preclinical Data of Drug Candidate
Doubling Down On Gain Therapeutics (NASDAQ:GANX)
GT-02287: GCase-targeting small molecule therapy for GBA1
Gain Therapeutics, Inc.
Gain Therapeutics Promotes Matthias Alder to CEO
Gain Therapeutics' SEE-Tx Platform Unique when compared to Other
